A citation-based method for searching scientific literature

Arman Qamar, Robert P Giugliano, Anthony C Keech, Julia F Kuder, Sabina A Murphy, Christopher E Kurtz, Scott M Wasserman, Peter S Sever, Terje R Pedersen, Marc S Sabatine. JAMA Cardiol 2019
Times Cited: 22







List of co-cited articles
159 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Marc S Sabatine, Robert P Giugliano, Anthony C Keech, Narimon Honarpour, Stephen D Wiviott, Sabina A Murphy, Julia F Kuder, Huei Wang, Thomas Liu, Scott M Wasserman,[...]. N Engl J Med 2017
54

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Gregory G Schwartz, P Gabriel Steg, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Jay M Edelberg, Shaun G Goodman, Corinne Hanotin, Robert A Harrington,[...]. N Engl J Med 2018
50

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
François Mach, Colin Baigent, Alberico L Catapano, Konstantinos C Koskinas, Manuela Casula, Lina Badimon, M John Chapman, Guy G De Backer, Victoria Delgado, Brian A Ference,[...]. Eur Heart J 2020
36

Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk.
Michelle L O'Donoghue, Sergio Fazio, Robert P Giugliano, Erik S G Stroes, Estella Kanevsky, Ioanna Gouni-Berthold, KyungAh Im, Armando Lira Pineda, Scott M Wasserman, Richard Češka,[...]. Circulation 2019
262
31

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
Jennifer G Robinson, Michel Farnier, Michel Krempf, Jean Bergeron, Gérald Luc, Maurizio Averna, Erik S Stroes, Gisle Langslet, Frederick J Raal, Mahfouz El Shahawy,[...]. N Engl J Med 2015
31

Diagnosing Resistance to a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor.
Michael D Shapiro, Joshua Miles, Hagai Tavori, Sergio Fazio. Ann Intern Med 2018
24
27

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.
Jonathan C Cohen, Eric Boerwinkle, Thomas H Mosley, Helen H Hobbs. N Engl J Med 2006
27

Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials.
Harold E Bays, Robert S Rosenson, Marie T Baccara-Dinet, Michael J Louie, Desmond Thompson, G Kees Hovingh. Cardiovasc Drugs Ther 2018
14
42

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.
Alberico L Catapano, Ian Graham, Guy De Backer, Olov Wiklund, M John Chapman, Heinz Drexel, Arno W Hoes, Catriona S Jennings, Ulf Landmesser, Terje R Pedersen,[...]. Eur Heart J 2016
27

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.
Kausik K Ray, Ulf Landmesser, Lawrence A Leiter, David Kallend, Robert Dufour, Mahir Karakas, Tim Hall, Roland P T Troquay, Traci Turner, Frank L J Visseren,[...]. N Engl J Med 2017
431
27

Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials.
S Matthijs Boekholdt, G Kees Hovingh, Samia Mora, Benoit J Arsenault, Pierre Amarenco, Terje R Pedersen, John C LaRosa, David D Waters, David A DeMicco, R John Simes,[...]. J Am Coll Cardiol 2014
362
27

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.
Kausik K Ray, R Scott Wright, David Kallend, Wolfgang Koenig, Lawrence A Leiter, Frederick J Raal, Jenna A Bisch, Tara Richardson, Mark Jaros, Peter L J Wijngaard,[...]. N Engl J Med 2020
237
27

Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab.
Paul M Ridker, Jean-Claude Tardif, Pierre Amarenco, William Duggan, Robert J Glynn, J Wouter Jukema, John J P Kastelein, Albert M Kim, Wolfgang Koenig, Steven Nissen,[...]. N Engl J Med 2017
201
22

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.
Marianne Abifadel, Mathilde Varret, Jean-Pierre Rabès, Delphine Allard, Khadija Ouguerram, Martine Devillers, Corinne Cruaud, Suzanne Benjannet, Louise Wickham, Danièle Erlich,[...]. Nat Genet 2003
22

Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9.
Jonathan B Edmiston, Nathan Brooks, Hagai Tavori, Jessica Minnier, Bart Duell, Jonathan Q Purnell, Tina Kaufman, Cezary Wojcik, Szilard Voros, Sergio Fazio,[...]. J Clin Lipidol 2017
32
22

Application of PCSK9 Inhibitors in Practice.
Tina M Kaufman, Bruce A Warden, Jessica Minnier, Joshua R Miles, P Barton Duell, Jonathan Q Purnell, Cezary Wojcik, Sergio Fazio, Michael D Shapiro. Circ Res 2019
38
22

Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans.
Gissette Reyes-Soffer, Marianna Pavlyha, Colleen Ngai, Tiffany Thomas, Stephen Holleran, Rajasekhar Ramakrishnan, Wahida Karmally, Renu Nandakumar, Nelson Fontanez, Joseph Obunike,[...]. Circulation 2017
138
22

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.
Frederick J Raal, Narimon Honarpour, Dirk J Blom, G Kees Hovingh, Feng Xu, Rob Scott, Scott M Wasserman, Evan A Stein. Lancet 2015
477
22

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.
Marc S Sabatine, Robert P Giugliano, Stephen D Wiviott, Frederick J Raal, Dirk J Blom, Jennifer Robinson, Christie M Ballantyne, Ransi Somaratne, Jason Legg, Scott M Wasserman,[...]. N Engl J Med 2015
22

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.
Brian A Ference, Henry N Ginsberg, Ian Graham, Kausik K Ray, Chris J Packard, Eric Bruckert, Robert A Hegele, Ronald M Krauss, Frederick J Raal, Heribert Schunkert,[...]. Eur Heart J 2017
22

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
Frederick J Raal, David Kallend, Kausik K Ray, Traci Turner, Wolfgang Koenig, R Scott Wright, Peter L J Wijngaard, Danielle Curcio, Mark J Jaros, Lawrence A Leiter,[...]. N Engl J Med 2020
158
22

Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER.
Björn W Karlson, Olov Wiklund, Michael K Palmer, Stephen J Nicholls, Pia Lundman, Philip J Barter. Eur Heart J Cardiovasc Pharmacother 2016
62
18

Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial.
Sripal Bangalore, Andrei Breazna, David A DeMicco, Chuan-Chuan Wun, Franz H Messerli. J Am Coll Cardiol 2015
112
18

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.
Paul M Ridker, James Revkin, Pierre Amarenco, Robert Brunell, Madelyn Curto, Fernando Civeira, Marcus Flather, Robert J Glynn, Jean Gregoire, J Wouter Jukema,[...]. N Engl J Med 2017
374
18

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.
Robert P Giugliano, Terje R Pedersen, Jeong-Gun Park, Gaetano M De Ferrari, Zbigniew A Gaciong, Richard Ceska, Kalman Toth, Ioanna Gouni-Berthold, Jose Lopez-Miranda, François Schiele,[...]. Lancet 2017
308
18

Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab.
Michael D Shapiro, Jessica Minnier, Hagai Tavori, Helina Kassahun, Andrea Flower, Ransi Somaratne, Sergio Fazio. J Am Heart Assoc 2019
32
18

Cognitive Function in a Randomized Trial of Evolocumab.
Robert P Giugliano, François Mach, Kenton Zavitz, Christopher Kurtz, Kyungah Im, Estella Kanevsky, Jingjing Schneider, Huei Wang, Anthony Keech, Terje R Pedersen,[...]. N Engl J Med 2017
246
18

Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics.
Gerald F Watts, Dick C Chan, Ransi Somaratne, Scott M Wasserman, Rob Scott, Santica M Marcovina, P Hugh R Barrett. Eur Heart J 2018
79
18


Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients.
Olivier Descamps, Joanne E Tomassini, Jianxin Lin, Adam B Polis, Arvind Shah, Philippe Brudi, Mary E Hanson, Andrew M Tershakovec. Atherosclerosis 2015
18
22

Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management.
Erik S Stroes, Paul D Thompson, Alberto Corsini, Georgirene D Vladutiu, Frederick J Raal, Kausik K Ray, Michael Roden, Evan Stein, Lale Tokgözoğlu, Børge G Nordestgaard,[...]. Eur Heart J 2015
715
18

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study.
Dean J Kereiakes, Jennifer G Robinson, Christopher P Cannon, Christelle Lorenzato, Robert Pordy, Umesh Chaudhari, Helen M Colhoun. Am Heart J 2015
240
18

Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS).
Konstantinos C Koskinas, Stephan Windecker, Giovanni Pedrazzini, Christian Mueller, Stéphane Cook, Christian M Matter, Olivier Muller, Jonas Häner, Baris Gencer, Carmela Crljenica,[...]. J Am Coll Cardiol 2019
54
18

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
Frederick J Raal, Evan A Stein, Robert Dufour, Traci Turner, Fernando Civeira, Lesley Burgess, Gisle Langslet, Russell Scott, Anders G Olsson, David Sullivan,[...]. Lancet 2015
473
18

Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?
Wieneke Dijk, Cédric Le May, Bertrand Cariou. Trends Endocrinol Metab 2018
22
13

Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.
Peter Willeit, Paul M Ridker, Paul J Nestel, John Simes, Andrew M Tonkin, Terje R Pedersen, Gregory G Schwartz, Anders G Olsson, Helen M Colhoun, Florian Kronenberg,[...]. Lancet 2018
194
13

The Evolving Future of PCSK9 Inhibitors.
Robert S Rosenson, Robert A Hegele, Sergio Fazio, Christopher P Cannon. J Am Coll Cardiol 2018
83
13

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role.
Frederick J Raal, Robert P Giugliano, Marc S Sabatine, Michael J Koren, Dirk Blom, Nabil G Seidah, Narimon Honarpour, Armando Lira, Allen Xue, Padmaja Chiruvolu,[...]. J Lipid Res 2016
133
13

PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo: An Effect Blunted by Alirocumab.
Elise F Villard, Aurélie Thedrez, Jorg Blankenstein, Mikaël Croyal, Thi-Thu-Trang Tran, Bruno Poirier, Jean-Christophe Le Bail, Stéphane Illiano, Estelle Nobécourt, Michel Krempf,[...]. JACC Basic Transl Sci 2016
66
13

An evaluation of alirocumab for the treatment of hypercholesterolemia.
Michel Farnier. Expert Rev Cardiovasc Ther 2015
18
16

Application of PCSK9 Inhibitors in Practice: Challenges and Opportunities.
Tina M Kaufman, P Barton Duell, Jonathan Q Purnell, Cezary Wójcik, Sergio Fazio, Michael D Shapiro. Circ Res 2017
23
13

A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.
Kevin Fitzgerald, Suellen White, Anna Borodovsky, Brian R Bettencourt, Andrew Strahs, Valerie Clausen, Peter Wijngaard, Jay D Horton, Jorg Taubel, Ashley Brooks,[...]. N Engl J Med 2017
356
13

The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice.
Christine Landlinger, Marianne G Pouwer, Claudia Juno, José W A van der Hoorn, Elsbet J Pieterman, J Wouter Jukema, Guenther Staffler, Hans M G Princen, Gergana Galabova. Eur Heart J 2017
120
13

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice.
Thomas A Lagace, David E Curtis, Rita Garuti, Markey C McNutt, Sahng Wook Park, Heidi B Prather, Norma N Anderson, Y K Ho, Robert E Hammer, Jay D Horton. J Clin Invest 2006
470
13

Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing.
Jayaprakash K Nair, Jennifer L S Willoughby, Amy Chan, Klaus Charisse, Md Rowshon Alam, Qianfan Wang, Menno Hoekstra, Pachamuthu Kandasamy, Alexander V Kel'in, Stuart Milstein,[...]. J Am Chem Soc 2014
504
13

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis.
Eliano Pio Navarese, Michalina Kolodziejczak, Volker Schulze, Paul A Gurbel, Udaya Tantry, Yingfeng Lin, Maximilian Brockmeyer, David E Kandzari, Julia M Kubica, Ralph B D'Agostino,[...]. Ann Intern Med 2015
294
13

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Christopher P Cannon, Michael A Blazing, Robert P Giugliano, Amy McCagg, Jennifer A White, Pierre Theroux, Harald Darius, Basil S Lewis, Ton Oude Ophuis, J Wouter Jukema,[...]. N Engl J Med 2015
13

Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
Christopher P Cannon, Irfan Khan, Alexa C Klimchak, Matthew R Reynolds, Robert J Sanchez, William J Sasiela. JAMA Cardiol 2017
65
13

Cost-Effectiveness of Alirocumab: A Just-in-Time Analysis Based on the ODYSSEY Outcomes Trial.
Dhruv S Kazi, Joanne Penko, Pamela G Coxson, David Guzman, Pengxiao C Wei, Kirsten Bibbins-Domingo. Ann Intern Med 2019
34
13

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
Steven E Nissen, Erik Stroes, Ricardo E Dent-Acosta, Robert S Rosenson, Sam J Lehman, Naveed Sattar, David Preiss, Eric Bruckert, Richard Ceška, Norman Lepor,[...]. JAMA 2016
288
13


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.